Between China, Wall Street and Nasdaq Stockholm | Market Signal #4
In the summer edition of BioStock Market Signal, host Cecilia Hallström turns her attention to global capital flows and what they mean for the Nordic life science sector. In conversation with two heavyweight voices from the industry’s financial heartland, we get perspectives ranging from China’s fast-growing role in Big Pharma dealmaking to the current state of Nordic listings.
We begin with Jonathan Gertler, founder and CEO of Back Bay Life Science Advisors, who shares his view on the current global state of the sector. He analyses the trends driving IPOs and capital raising internationally, how China’s biotech companies are challenging the US and Europe with increasingly fast and cost-efficient clinical data, and what Nordic companies need to understand in order to attract US capital. Gertler also shares his best advice for life science CEOs looking to stand out in a market where investors demand ever clearer clinical and commercial proof.
The episode concludes with Adam Kostyal, President of Nasdaq Stockholm, who gives his take on the current mood in the Nordic capital markets and whether we’re seeing genuine signs of recovery in listings and financing activity. Kostyal discusses what a life science company actually needs to have in place today before a Stockholm listing, and how the gap to US late-stage capital looks. He also shares his view on what it will take for Europe to compete with the US and China on a level playing field.